Tag: SGLT2 inhibitors

Type 2 Diabetes Medication Improves Liver Health in Mice Fed High Fat Diet

sarah JonasResearch Alert

Article title: SGLT2 inhibition leads to a restoration of hepatic and circulating metabolites involved in the folate cycle and pyrimidine biosynthesis Authors: Ileana Mendez Espinoza, Elijah N. D. Choos, Carolyn M. Ecelbarger, Blythe D. Shepard From the authors: “Here, we…

SGLT2 Inhibitor Empagliflozin Is Shown to Be Safe and Effective for Treating Patients Who Have Suffered a Heart Attack

sarah JonasResearch Results

The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a Mount Sinai-led global team of researchers has shown.

Patients with diabetes and gout may benefit from treatment with SGLT2is

sarah JonasResearch Results

A study of persons with gout and type 2 diabetes found that the use of sodium–glucose cotransporter-2 inhibitors (SGLT2is) may reduce recurrent flares and gout-primary emergency department (ED) visits and hospitalizations compared to treatment with dipeptidyl peptidase 4 inhibitors (DPP-4is). SGLT2is may also provide greater cardiovascular benefits in this population. The findings are published in Annals of Internal Medicine.

SGLT2 inhibitors and GLP1 receptor antagonists improve type-2 diabetes outcomes, but are not cost effective

sarah JonasResearch Results

A cost-effectiveness study of sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP1) receptor agonists has found that the use of these medications as first-line treatment for type-2 diabetes would improve outcomes, but their costs would need to decrease by at least 70 percent to be cost-effective. The study is published in Annals of Internal Medicine.